Potential role of rituximab in metastatic castrate-resistant prostate cancer
- Resource Type
- Authors
- Poorva Bindal; Jessica M. Clement; Lisa M. Holle; Sharif Aa Jalil
- Source
- Journal of Oncology Pharmacy Practice. 25:1509-1511
- Subject
- Male
Oncology
Bendamustine
medicine.medical_specialty
medicine.medical_treatment
Follicular lymphoma
Castrate-resistant prostate cancer
Targeted therapy
Androgen deprivation therapy
03 medical and health sciences
Prostate cancer
Antineoplastic Agents, Immunological
0302 clinical medicine
Internal medicine
medicine
Humans
Pharmacology (medical)
Aged
business.industry
Androgen Antagonists
medicine.disease
Prostatic Neoplasms, Castration-Resistant
030220 oncology & carcinogenesis
Rituximab
business
Infiltration (medical)
030215 immunology
medicine.drug
- Language
- ISSN
- 1477-092X
1078-1552
Nearly all men with prostate cancer who are treated with androgen deprivation therapy develop disease progression. There is considerable evidence to suggest that CXCL 13 released by tumor cells leads to B-cell infiltration into the prostate cells. This B-cell infiltration has been postulated to play a role in development of disease progression following androgen-deprivation therapies. We present a case of a patient who achieved remission of metastatic castrate-resistant prostate cancer after receiving rituximab and bendamustine for the treatment of follicular lymphoma. The findings in this report suggest that further investigation is warranted for utilizing B-cell targeted therapy in delaying progression of castrate-resistant prostate cancer.